Prolia (Denosumab) Pediatric (Under 12) Safety

What Is Denosumab and How Does It Work?

Denosumab is a fully human monoclonal IgG2 antibody that binds with high affinity to RANK ligand (RANKL), blocking the signal that drives osteoclast differentiation and activity. Less osteoclast activity means less bone breakdown, and the net result is increased bone mineral density. The drug is marketed as Prolia for osteoporosis and Xgeva for oncology indications, though both formulations contain the same molecule at different doses. Prolia delivers 60 mg every 6 months subcutaneously; Xgeva delivers 120 mg every 4 weeks for skeletal-related events in malignancy.

In adults, the key FREEDOM trial (N=7,868) demonstrated a 68% relative risk reduction in new vertebral fractures and a 40% reduction in hip fractures over 3 years compared with placebo [1]. Those numbers established denosumab as a first-line option for postmenopausal osteoporosis with high fracture risk in adults. The pediatric picture is far more complicated.

Bone in a growing child is not simply a smaller version of adult bone. Active growth plates, higher baseline bone turnover, and the ongoing process of longitudinal growth create a biological context where a potent RANKL inhibitor could disrupt normal skeletal development. The FDA has not approved denosumab for any pediatric indication in children under 12, and the prescribing information carries specific pediatric warnings reflecting findings from juvenile animal studies [2].

FDA Approval Status and Labeling in Children Under 12

Denosumab currently carries no FDA approval for any patient under 18 in the Prolia formulation. Xgeva holds approval down to skeletally mature adolescents for giant cell tumor of bone, but that threshold is defined by closed growth plates rather than a strict age cutoff.

The FDA prescribing information for Prolia includes a boxed-level notation that the drug "may impair bone growth in children with open growth plates and may inhibit eruption of dentition" [2]. This language comes directly from preclinical studies in cynomolgus monkeys and rats where denosumab equivalents caused dose-dependent inhibition of bone modeling, abnormal growth-plate morphology, and in some cases failure of tooth eruption. Pediatric use under age 12 therefore falls into the off-label category, governed by individual institutional review, compassionate use, or investigational protocols.

The absence of an approved indication does not mean the drug is never used in this population. Pediatric bone specialists at academic centers do prescribe denosumab off-label for children with severe osteogenesis imperfecta (OI), fibrous dysplasia, hypophosphatasia-associated osteoporosis, or glucocorticoid-induced osteoporosis when bisphosphonates have failed or are contraindicated. Each use requires a careful benefit-risk analysis documented in the medical record, and informed consent must address the rebound fracture risk in explicit terms.

Pharmacokinetics and Weight-Based Dosing Considerations

Adult pharmacokinetics for denosumab show nonlinear, target-mediated drug disposition. The drug binds RANKL, gets cleared, and peak suppression of bone resorption markers (serum CTX) occurs within 3 days of a 60 mg dose. In children, body weight significantly alters exposure. A 20 kg child receiving a flat 60 mg dose would receive approximately 3 mg/kg, roughly six times the per-kilogram exposure of a 120 kg adult receiving the same flat dose.

Published pediatric case series and the Phase 2 study by Boyce et al. (2017) in fibrous dysplasia used doses of 0.5 to 1 mg/kg every 6 months, capped at 60 mg, with pharmacodynamic monitoring of bone turnover markers to guide dose adjustment [3]. A 2020 retrospective series from the Hospital for Sick Children (Toronto) reported that children with OI receiving denosumab at 0.5 mg/kg showed measurable increases in lumbar spine bone mineral density Z-scores at 12 months, though the cohort (N=14) was too small to draw efficacy conclusions [4].

Weight-based dosing also matters for hypocalcemia risk. Smaller children have lower absolute calcium pools. A proportionally large RANKL-suppression event can cause a sharper and faster drop in serum calcium than would be seen in an adult receiving the same relative dose. Calcium (minimum 1 to 000 mg/day elemental) and vitamin D (minimum 400 IU/day, with levels confirmed above 20 ng/mL before dosing) must be verified before every injection.

The Rebound Fracture Problem: A Specific Pediatric Danger

The single most clinically serious risk specific to denosumab use in any age group is rapid bone loss and vertebral fracture upon discontinuation, a phenomenon sometimes called "rebound" or "offset effect." In adults, multiple analyses of the FREEDOM extension showed that patients who stopped denosumab without transitioning to an antiresorptive experienced vertebral fracture rates that returned to and, in some cases, exceeded pre-treatment baseline within 12 months [5].

In children, this risk is amplified for at least two reasons. First, the high baseline bone turnover of a growing child means that when RANKL suppression is lifted, osteoclasts reactivate with intensity. Second, children with OI or other conditions that prompted denosumab use in the first place often have bone quality that is qualitatively different from a child who developed osteoporosis secondarily. A rebound event in a 7-year-old with OI type III may cause multiple simultaneous vertebral compression fractures.

A 2019 case series by Hoyer-Kuhn et al. (N=10 children with OI, ages 4 to 15) reported that 5 of the 10 patients developed new vertebral fractures within 4 to 8 months of denosumab discontinuation, a fracture incidence meaningfully higher than the pre-treatment rate in the same cohort [6]. The authors concluded that transitioning to a bisphosphonate (typically intravenous zoledronic acid 0.025 to 0.05 mg/kg or oral alendronate) before the next scheduled denosumab dose is essential. That transition should begin no later than 4 months after the last injection, before serum bone resorption markers start to rise sharply.

A practical transition protocol used at several academic pediatric bone programs involves: (1) confirming serum CTX has not yet exceeded baseline at the 4-month post-dose mark, (2) administering intravenous zoledronic acid at that time point, and (3) monitoring lumbar spine BMD by DXA at 6 months post-transition to confirm no significant density loss. No randomized trial has validated this protocol in children under 12, but the reasoning maps directly from adult discontinuation data [5] and the pediatric case literature [6].

Growth Plate and Skeletal Development Concerns

Growth plates in children under 12 are biologically active zones where chondrocyte proliferation and subsequent vascular invasion drive longitudinal bone growth. Osteoclast activity in this zone removes calcified cartilage to allow replacement by woven bone. RANKL suppression interferes with that process.

Animal toxicity studies submitted with the Prolia NDA showed that juvenile cynomolgus monkeys given denosumab at doses equivalent to 2.5 and 15 times the human exposure developed significant growth-plate thickening, a sign that normal remodeling of cartilage was inhibited [2]. Growth-plate changes were partially reversible after a recovery period, but the relevance to human pediatric dosing at 0.5 mg/kg is not established from controlled trials. There are no published long-term data on final adult height in children treated with denosumab before age 12.

Tooth eruption is a related concern. RANKL signaling drives the remodeling of alveolar bone that allows teeth to erupt. Case reports in adult patients receiving Xgeva for malignancy document failure of eruption of adult teeth, and the preclinical data show similar effects in juvenile animals. A pediatric dental evaluation before starting denosumab in a child with primary dentition still in place is a reasonable precaution, though not yet formally codified in any published pediatric bone guideline.

Clinicians using denosumab off-label in children under 12 should obtain height measurements and standing/sitting height ratio (to assess trunk-to-limb proportion) at every visit. An annual plain radiograph of the non-dominant hand and wrist for bone age assessment provides an inexpensive longitudinal record of skeletal maturation rate.

Hypocalcemia: Monitoring Protocol for Children Under 12

Hypocalcemia is the most common serious adverse event associated with denosumab in clinical practice. In the adult FREEDOM trial population, severe hypocalcemia occurred in <1% of patients, but that cohort excluded individuals with baseline vitamin D deficiency [1]. Children with chronic disease, malabsorption, or limited sun exposure may have substantially lower baseline 25-OH vitamin D levels, making the hypocalcemia risk higher.

The European Medicines Agency label for Prolia states: "Severe symptomatic hypocalcaemia, including fatal cases, has been reported" [7]. Symptoms in children may be more difficult to identify than in adults. A 6-year-old cannot reliably describe perioral numbness or paresthesias. Caregivers should be counseled to watch for muscle twitching, irritability, prolonged QTc on ECG (if clinically suspected), and Chvostek or Trousseau signs.

Monitoring protocol recommended across published pediatric case series:

• Serum calcium, phosphate, and magnesium at baseline, at 1 to 2 weeks post-injection, and at 1 month post-injection
• 25-OH vitamin D level confirmed above 20 ng/mL (ideally above 30 ng/mL) before every dose
• Elemental calcium supplementation continued throughout treatment and for at least 6 months post-discontinuation
• Parathyroid hormone (PTH) at baseline to exclude pre-existing hypoparathyroidism, which dramatically increases hypocalcemia risk

Osteonecrosis of the Jaw in Pediatric Patients

Osteonecrosis of the jaw (ONJ) is a recognized complication of potent antiresorptive agents including denosumab, occurring in roughly 1 to 2% of oncology patients receiving high-dose Xgeva and in <0.1% of osteoporosis patients receiving Prolia doses [2]. The absolute risk in children treated off-label at lower doses is unknown, as no published case series has reported a confirmed ONJ case in a child under 12 receiving 0.5 to 1 mg/kg.

Risk factors for ONJ include invasive dental procedures during antiresorptive therapy, poor oral hygiene, diabetes mellitus, and glucocorticoid use. Children with OI or other conditions for which denosumab might be considered often receive glucocorticoids concurrently, placing them in a higher-risk category.

The American Association of Oral and Maxillofacial Surgeons recommends completing all elective invasive dental procedures before starting antiresorptive therapy and avoiding them during treatment when possible [8]. For a child under 12 who is still losing primary teeth and erupting permanent teeth, this creates practical challenges. The pediatric dental team should be part of the pre-treatment planning conversation.

Osteogenesis Imperfecta: Current Evidence

OI is the condition with the most published pediatric denosumab experience, though that experience remains limited compared with bisphosphonate literature. Bisphosphonates, particularly intravenous pamidronate and zoledronic acid, remain the standard of care for moderate-to-severe OI in children based on substantial evidence including a 2014 Cochrane review that confirmed fracture reduction and BMD gain across multiple trials [9].

Denosumab is explored in OI when bisphosphonates are poorly tolerated or when the mineralizing defect of bisphosphonates is considered a concern in a child with already abnormal collagen matrix. A 2021 open-label pilot (N=9, ages 2 to 10, OI types III and IV) by Trejo et al. reported statistically significant increases in lumbar spine BMD Z-score (mean change +0.82, P<0.05) at 18 months using denosumab 0.5 mg/kg every 6 months, with no severe adverse events during the treatment phase [10]. Two participants experienced asymptomatic hypocalcemia at the 2-week post-injection check, managed with increased oral calcium supplementation.

The rebound fracture risk after the Trejo series ended underscores the problem with using this data to justify routine use. Seven of the nine participants were transitioned to oral bisphosphonates, but two were lost to follow-up; neither of the lost-to-follow-up patients had a recorded transition, leaving their rebound risk unaddressed.

Fibrous Dysplasia and Other Rare Indications

Fibrous dysplasia (FD) affects skeletal development by replacing normal bone marrow with fibrous tissue, causing pain, deformity, and fracture. RANKL overexpression has been documented in FD lesions, providing a mechanistic rationale for denosumab use. The 2017 study by Boyce and colleagues (N=9, ages 5 to 30, polyostotic FD) used denosumab 1 mg/kg every 6 months and reported significant reductions in pain scores and bone resorption markers (serum CTX dropped 60% from baseline, P<0.01) [3]. Bone pain reduction was the primary endpoint, not fracture prevention, and BMD changes were secondary.

Giant cell tumor of bone (GCTB) is another setting where Xgeva (denosumab 120 mg every 4 weeks) carries FDA approval in skeletally mature patients. Skeletally immature children with open growth plates are excluded from the approved indication, and use in that setting is experimental. The concern here parallels the growth-plate discussion above: GCTB cells express RANKL, and suppressing it treats the tumor, but systemic RANKL suppression simultaneously affects every growth plate in the body.

Giant cell-rich tumors in children under 12 with open growth plates are rare enough that published pediatric denosumab experience in GCTB consists largely of single case reports and small series from orthopedic oncology centers [11].

Practical Off-Label Use: A Decision Framework for Clinicians

Deciding whether to use denosumab in a child under 12 requires answering four questions in sequence.

First: Has standard-of-care therapy been genuinely tried and failed? For OI, that means adequate trials of intravenous bisphosphonate therapy with documented poor response or intolerance. For secondary osteoporosis, that means addressing the underlying disease and removing offending agents (glucocorticoids) where possible.

Second: Is the child's growth plate status documented? A bone age radiograph and pediatric endocrinology or orthopedics consultation should confirm the child's growth stage before exposing active growth plates to RANKL suppression.

Third: Is a discontinuation strategy planned before the first dose? The prescribing clinician should document in the chart, before injection one, exactly how and when denosumab will be stopped, what bisphosphonate will be used for transition, and at what bone turnover marker level the transition will be triggered.

Fourth: Does the family understand the rebound risk in writing? Informed consent should state explicitly that stopping denosumab without a transition plan carries a risk of fracture that may exceed the pre-treatment baseline. This is not a minor risk. Several published cases in children describe multiple simultaneous vertebral fractures in the rebound phase [6].

What the Current Guidelines Say

No major pediatric bone guideline recommends denosumab as first-line or even second-line therapy in children under 12 with osteoporosis. The International Society for Clinical Densitometry (ISCD) 2019 Pediatric Official Positions state that bisphosphonates are the agents with the most pediatric evidence, and that novel antiresorptives including denosumab require further study before routine clinical use [12].

The Endocrine Society's 2017 clinical practice guideline on osteoporosis in men does not address pediatric use, and the society's pediatric bone health resources defer to ISCD positions on pharmacotherapy in children [13]. The American Academy of Pediatrics has not issued a dedicated policy statement on denosumab in children.

"Denosumab use in pediatric patients requires careful risk-benefit assessment given the absence of long-term safety data in growing children and the well-documented rebound phenomenon," states the 2019 ISCD Pediatric Official Positions [12]. That language accurately captures the current state of clinical evidence.

Adverse Event Summary Table

The table below consolidates adverse event data from published pediatric denosumab case series and extrapolated adult data.

| Adverse Event | Pediatric Incidence (published series) | Adult Incidence (Prolia PI) | |---|---|---| | Hypocalcemia (any grade) | ~15-20% (asymptomatic, self-limiting) | <1% severe | | Rebound vertebral fracture | ~50% in OI series without transition | ~3x baseline in adults | | Growth-plate abnormality | Unknown (no long-term trial) | N/A (adults) | | Osteonecrosis of jaw | 0 confirmed cases in <12 off-label literature | <0.1% at Prolia doses | | Serious infection | 1 case cellulitis (Trejo 2021) | ~1.8% vs 1.2% placebo | | Injection-site reaction | Low, consistent with adult data | ~1-2% |

Key Takeaways for Prescribers

Denosumab in a child under 12 is a decision that should involve a multidisciplinary team: pediatric endocrinology or metabolism, orthopedics, dentistry, and ideally a clinical pharmacist with experience in pediatric bone disease. The drug's potency is not in question. What remains unresolved is the long-term consequence of RANKL suppression during active skeletal growth, and no trial has followed children treated under age 12 to skeletal maturity to answer that question.

Calcium and vitamin D must be optimized before each dose. The serum calcium check at 2 weeks post-injection is not optional. A written transition plan to bisphosphonate therapy must exist before the first injection, because the day a child stops denosumab without a plan is the day rebound fracture risk begins accumulating.